Seroprevalence of RSV IgG Antibodies Across Age Groups in Poland After the COVID-19 Pandemic: Data from the 2023/2024 Epidemic Season

<b>Background/Objectives:</b> Respiratory syncytial virus (RSV) is a leading cause of respiratory infections across all age groups, with the greatest burden observed in young children and older adults. The COVID-19 pandemic significantly disrupted RSV circulation, resulting in an immunit...

Full description

Saved in:
Bibliographic Details
Main Authors: Barbara Poniedziałek, Wiktoria Majewska, Katarzyna Kondratiuk, Aleksander Masny, Anna Poznańska, Karol Szymański, Katarzyna Łuniewska, Emilia Czajkowska, Bartosz Mańkowski, Lidia B. Brydak, Krzysztof Tomasiewicz, Robert Flisiak, Piotr Rzymski
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/13/7/741
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<b>Background/Objectives:</b> Respiratory syncytial virus (RSV) is a leading cause of respiratory infections across all age groups, with the greatest burden observed in young children and older adults. The COVID-19 pandemic significantly disrupted RSV circulation, resulting in an immunity gap and altered transmission dynamics. This study aimed to assess the seroprevalence of anti-RSV IgG antibodies in the Polish population during the 2023/2024 epidemic season. To our knowledge, this is the first study to characterize RSV seroprevalence at the population level in Poland. <b>Methods:</b> A total of 700 serum samples from individuals across different age groups were analyzed using a commercial assay to detect anti-RSV IgG antibodies. Seroprevalence and antibody levels, expressed as the index of positivity (IP), were examined by age and sex. <b>Results:</b> The overall seroprevalence of anti-RSV IgG antibodies was 91.4%. Antibody positivity increased markedly from 35.5% in infants aged 0–1 years to over 90% in children aged 4–5 years, reaching nearly universal levels in older age groups, including 99.1% in adults aged ≥60 years. Median IP values also rose with age, peaking in individuals aged ≥60 years. No significant differences in seroprevalence were observed between sexes, though older men showed slightly higher median IP values, potentially reflecting greater cumulative RSV exposure. <b>Conclusions:</b> This study provides key insights into the post-pandemic landscape of RSV immunity in Poland. The high seroprevalence across most age groups underscores widespread prior exposure, while the lower rates in infants highlight a continued vulnerability. These findings support the development and implementation of targeted immunization strategies, particularly for infants and older adults.
ISSN:2076-393X